Something went wrong

We encountered an unexpected error, we encourage you to try again later.

We're here to help

Should you have additional questions please contact PfizerPro customer service.

Representatives are available:
Monday-Friday 8:00am to 9:00pm Eastern time

Call 1 (800) 505-4426

PP-UNP-USA-5796
Order samples Unable to confirm your eligibility

Unfortunately, your registration is incomplete and we are unable to confirm your eligibility for sample ordering.

To gain access please enter your professional information within your account.

Open your account We're here to help

Should you need further support updating your account information, please contact PfizerPro customer service.

Representatives are available:
Monday-Friday 8:00am to 9:00pm Eastern time

Call 1 (800) 505-4426

​​​​​​​PP-UNP-USA-5796
Order samples
Thank you for expressing interest in Pfizer samples. Currently there are no samples available to order. Samples renew periodically, we encourage you to check back soon.
 We're here to help

Should you have additional questions please contact PfizerPro customer service.

Representatives are available:
Monday-Friday 8:00am to 9:00pm Eastern time

Call 1 (800) 505-4426

​​​​​​​PP-UNP-USA-5796
Order samples

All samples available online to you are included below. Availability is updated periodically.

PP-UNP-USA-5796
Important Notice

Savings cards will be shipped with Product Samples, if applicable.

Signature

Use your mouse, finger, or stylus to sign below.

Legal Notice

I certify that I am a licensed prescriber, eligible to request and receive the drug samples listed in the quantities indicated. I am also confirming that these samples will be used exclusively for the medical treatment of my patients in conformity with all relevant state and/or local prescribing and dispensing requirements. My signature will also serve as confirmation of my receipt of these medications, if delivered by a company representative, or my intention to acknowledge them upon delivery to my medical office if shipped via common carrier. I understand that these samples cannot be sold, traded, bartered returned for credit or utilized to seek or obtain reimbursement.

Your order has been placed

We have received your order and are getting it ready

More to explore Patient assistance

Download available co-pay cards and patient savings offers across select Pfizer products.

Explore patient assistance Loading Vaccines

Find out more about the diseases, treatments and prevention methods that are impacted by our Pfizer Vaccine portfolio.

Explore Vaccines Loading
PP-UNP-USA-5796
Leave ordering?

Changes you have made will not be saved.

This site is intended for U.S. healthcare professionals.

For patient resources and support click HERE

Menu

Close

Sign InLog OutTherapy AreasProductsOrder VaccinesOrder SamplesOrderMaterialsCo-pay Cards & Patient Savings OffersRequest SamplesHospital ProductsVaccinesPatient AssistancePfizer Oncology TogetherPfizer RxPathwaysPfizer Dermatology Patient AccessExplore ContentEventsMaterialsVideosContact

Menu

Close

HomeCDC RecommendationAbout RSVAbout ABRYSVOAbout ABRYSVOStudy Design & Efficacy ProfileSafety ProfileDosing, Storage, ReconstitutionOrder ABRYSVOResourcesResourcesMaternal RSV Vaccine PlannerHealth Plan CoverageRequest A RepMaterialsVideosEventsMaterialsVideos
Prescribing InformationIndications AdultPatient Site
ACOG supports the CDC recommendation for ABRYSVO®1ABRYSVO is recommended for pregnant individuals as a one-time dose at 32 weeks and 0 days' through 36 weeks and 6 days' gestation, using seasonal administration (September through January in most of the U.S.), for prevention of RSV-associated LRTI in infants aged <6 months2*View the ACOG website for more informationLoadingMultiple obstetric care organizations support the CDC's recommendation of ABRYSVO for maternal RSV vaccination, including3:

American College of Obstetricians and Gynecologists (ACOG)

American Academy of Family Physicians (AAFP)

American College of Nurse-Midwives (ACNM)

Association of Women's Health, Obstetric and Neonatal Nurses (AWHONN)

National Association of Nurse Practitioners in Women's Health (NPWH)

Society for Maternal-Fetal Medicine (SMFM)

View the full press releaseLoadingLoadingCDC Clinical Guidance on ABRYSVO
View the full MMWR publicationLoading

Seasonal administration

  • ABRYSVO is recommended for pregnant individuals at 32 weeks and 0 days' through 36 weeks and 6 days' gestation, from September through January in most regions of the U.S.2
  • In jurisdictions with RSV seasonality that differs from most of the continental U.S., providers should follow state, local, or territorial guidance on timing of maternal vaccination with ABRYSVO2

Coadministration

  • According to the CDC, RSV vaccines can be coadministered with other adult vaccines, making it easier for patients to stay up to date with CDC recommendations. This may include vaccines such as seasonal influenza vaccines and Tdap vaccines2,4
  • In the ABRYSVO clinical trials, coadministration of ABRYSVO and Tdap was studied in non-pregnant women 18 to 49 years old and no safety concerns were identified5
  • If patients choose to get vaccines during different visits, there is no minimum waiting period between vaccines2,4
  • Available data on the safety and immunogenicity of coadministration of RSV vaccines with other vaccines are currently limited6

Additional Information

  • Currently, after maternal vaccination with ABRYSVO, additional doses are not recommended for subsequent pregnancies. Additional data are needed to determine whether additional seasonal doses during subsequent pregnancies are indicated, and ACIP might update recommendations in the future, as data become available2
  • Either ABRYSVO (maternal RSV preF vaccine) or a monoclonal antibody immunization is recommended to prevent severe RSV-LRTD in infants, but both are not needed for most infants2
ACIP=Advisory Committee on Immunization Practices; CDC=Centers for Disease Control and Prevention; LRTI=lower respiratory tract infection; MMWR=Morbidity and Mortality Weekly Report; preF=prefusion F; RSV=respiratory syncytial virus; RSV-LRTD=respiratory syncytial virus-associated lower respiratory tract disease; Tdap=tetanus, diphtheria, and pertussis. Maternal RSV Vaccine Planner

For eligible patients, this tool estimates the ABRYSVO vaccination window based upon estimated pregnancy due date, season, and location, consistent with the approved ABRYSVO indication and CDC recommendation.

 View the Planner LoadingInsurance coverageLearn more about coverage for ABRYSVO for eligible pregnant patients.Explore NowLoading Stock ABRYSVO

Make ABRYSVO available to your eligible patients by placing an order today.

 Order Now LoadingLearn about RSVDiscover the common virus that's particularly dangerous in infants.7,8Learn MoreLoading
Receive Updates About ABRYSVO Register NowLoading Request a Pfizer Sales Representative Connect Now Loading Receive Updates About ABRYSVO Register NowLoading Request a Pfizer Sales Representative Connect Now Loading
References:
American College of Obstetricians and Gynecologists. Maternal respiratory syncytial virus vaccination practice advisory. Updated September 2025. Accessed October 23, 2025. https://www.acog.org/clinical/clinical-guidance/practice-advisory/articles/2023/09/maternal-respiratory-syncytial-virus-vaccinationFleming-Dutra KE, Jones JM, Roper LE, et al. Use of the Pfizer respiratory syncytial virus vaccine during pregnancy for the prevention of respiratory syncytial virus–associated lower respiratory tract disease in infants: recommendations of the Advisory Committee on Immunization Practices — United States, 2023. MMWR Morb Mortal Wkly Rep. 2023;72(41):1115-1122.American Academy of Family Physicians. Academy greenlights federal actions on maternal RSV vaccine. Published October 2, 2023. Accessed October 23, 2025. https://www.aafp.org/news/health-of-the-public/maternal-rsv-vaccine-approval.htmlCenters for Disease Control and Prevention. Vaccine recommendations before, during, and after pregnancy. Updated June 24, 2024. Accessed October 23, 2025. https://www.cdc.gov/vaccines-pregnancy/recommended-vaccines/index.htmlABRYSVO (Respiratory Syncytial Virus Vaccine) Prescribing Information. Pfizer Inc; July 2025.Centers for Disease Control and Prevention. RSV vaccine guidance for adults. Updated July 8, 2025. Accessed October 23, 2025. https://www.cdc.gov/rsv/hcp/vaccine-clinical-guidance/adults.htmlCurns AT, Rha B, Lively JY, et al. Respiratory syncytial virus-associated hospitalizations among children <5 years old: 2016 to 2020. Pediatrics. 2024;153(3):e2023062574.Jain H, Schweitzer JW, Justice NA. Respiratory syncytial virus infection in children. Updated June 23, 2023. Accessed October 23, 2025. https://www.ncbi.nlm.nih.gov/books/NBK459215/

To report an adverse event, please call 1-800-438-1985

Pfizer for Professionals 1-800-505-4426

This site is intended only for U.S. healthcare professionals. The products discussed in this site may have different product labeling in different countries. The information provided is for educational purposes only.

© 2026 Pfizer Inc. All rights reserved.

PP-A1G-USA-2565
You are now leaving PfizerProYou are now leaving a Pfizer operated website. Links to all outside sites are provided as a resource to our visitors. Pfizer accepts no responsibility for the content of sites that are not owned and operated by Pfizer. 
PP-MCL-USA-0367
IndicationsABRYSVO is a vaccine indicated for:
  • active immunization for the prevention of lower respiratory tract disease (LRTD) caused by respiratory syncytial virus (RSV) in individuals 60 years of age and older
  • active immunization of pregnant individuals at 32 through 36 weeks gestational age for the prevention of LRTD and severe LRTD caused by RSV in infants from birth through 6 months of age
  • active immunization for the prevention of LRTD caused by RSV in individuals 18 through 59 years of age who are at increased risk for LRTD caused by RSV

Please click here for full Prescribing Information.
Important Safety Information
  • Do not administer ABRYSVO to individuals with a history of a severe allergic reaction (e.g., anaphylaxis) to any component of ABRYSVO
  • The results of a postmarketing observational study suggest an increased risk of Guillain-Barré syndrome during the 42 days following vaccination with ABRYSVO
  • A numerical imbalance in preterm births was observed compared to placebo in 2 clinical studies. Data are insufficient to establish or exclude a causal relationship between preterm birth and ABRYSVO. To avoid potential risk of preterm birth with use of ABRYSVO before 32 weeks of gestation, administer to pregnant individuals at 32 through 36 weeks gestational age
  • Appropriate medical treatment must be available in case of an anaphylactic reaction
  • Syncope (fainting) may occur with administration of injectable vaccines, including ABRYSVO. Procedures should be in place to avoid injury from fainting
  • Immunocompromised individuals, including those receiving immunosuppressive therapy, may have a diminished immune response to ABRYSVO
  • Vaccination with ABRYSVO may not protect all recipients
  • In clinical trials with adults aged 60+, the most commonly reported (≥10%) adverse reactions were fatigue (15.7%), headache (12.9%), pain at the injection site (10.6%), and muscle pain (10.2%)  
  • In clinical trials with adults aged 18-59, the most commonly reported (≥10%) adverse reactions were pain at the injection site (35.3%), muscle pain (24.4%), joint pain (12.4%), and nausea (11.8%)
  • In clinical trials with pregnant individuals, the most commonly reported (≥10%) adverse reactions were pain at the injection site (40.6%), headache (31.0%), muscle pain (26.5%), and nausea (20.0%)  
  • In clinical trials with infants born to pregnant individuals, low birth weight (5.1% ABRYSVO vs 4.3% placebo) and neonatal jaundice (7.3% ABRYSVO vs 6.9% placebo) were observed
Individuals who received ABRYSVO during pregnancy are encouraged to contact 1-800-616-3791 to enroll in a Pregnancy Exposure Registry.

Patients should always ask their healthcare providers for medical advice about adverse events. You are encouraged to report negative side effects of vaccines to the US Food and Drug Administration (FDA) and the Centers for Disease Control and Prevention (CDC). Visit http://www.vaers.hhs.gov or call 1-800-822-7967.

Please see full Prescribing Information for ABRYSVO. IndicationsABRYSVO is a vaccine indicated for:
  • active immunization for the prevention of lower respiratory tract disease (LRTD) caused by respiratory syncytial virus (RSV) in individuals 60 years of age and older
     
  • active immunization of pregnant individuals at 32 through 36 weeks gestational age for the prevention of LRTD and severe LRTD caused by RSV in infants from birth through 6 months of age
     
  • active immunization for the prevention of LRTD caused by RSV in individuals 18 through 59 years of age who are at increased risk for LRTD caused by RSV
You are now leaving PfizerProBy clicking Go to VaxAssist.com, you will be redirected to VaxAssist by Pfizer, where your patients can check eligibility and vaccine options. For additional information on ABRYSVO, please see Important Safety Information.